NO20064674L - Behandling av alvorlig lungebetennelse ervervet utenfor sykehus ved administrering av vevsfaktor pathway inhibitor - Google Patents

Behandling av alvorlig lungebetennelse ervervet utenfor sykehus ved administrering av vevsfaktor pathway inhibitor

Info

Publication number
NO20064674L
NO20064674L NO20064674A NO20064674A NO20064674L NO 20064674 L NO20064674 L NO 20064674L NO 20064674 A NO20064674 A NO 20064674A NO 20064674 A NO20064674 A NO 20064674A NO 20064674 L NO20064674 L NO 20064674L
Authority
NO
Norway
Prior art keywords
tissue factor
pathway inhibitor
hospital
factor pathway
treatment
Prior art date
Application number
NO20064674A
Other languages
English (en)
Inventor
Abla Creasy
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO20064674L publication Critical patent/NO20064674L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Det beskrives fremgangsmåter for profylaktisk eller terapeutisk behandling av alvorlig lungebetennelse og dette involverer administrering av vevfaktor pathway inhibitor (TFPI) eller en TFPI analog til pasienter som lider av eller risikerer utvikling av denne tilstand. Metoden involverer anvendelsen av en kontinuerlig, intravenøs infusjon av TFPI eller en TFPI analog, særlig i lave doser for å unngå ugunstige bivirkninger.
NO20064674A 2004-03-17 2006-10-16 Behandling av alvorlig lungebetennelse ervervet utenfor sykehus ved administrering av vevsfaktor pathway inhibitor NO20064674L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55468104P 2004-03-17 2004-03-17
PCT/US2005/009097 WO2005110059A2 (en) 2004-03-17 2005-03-17 Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)

Publications (1)

Publication Number Publication Date
NO20064674L true NO20064674L (no) 2006-11-29

Family

ID=35394617

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064674A NO20064674L (no) 2004-03-17 2006-10-16 Behandling av alvorlig lungebetennelse ervervet utenfor sykehus ved administrering av vevsfaktor pathway inhibitor

Country Status (16)

Country Link
US (1) US20080286279A1 (no)
EP (1) EP1729791A2 (no)
JP (1) JP2007532486A (no)
KR (1) KR20070007336A (no)
CN (1) CN101426520A (no)
AU (1) AU2005244249A1 (no)
BR (1) BRPI0508992A (no)
CA (1) CA2560103A1 (no)
IL (1) IL178115A0 (no)
MX (1) MXPA06010587A (no)
NO (1) NO20064674L (no)
RU (1) RU2006136267A (no)
SG (1) SG150552A1 (no)
TN (1) TNSN06295A1 (no)
WO (1) WO2005110059A2 (no)
ZA (1) ZA200608413B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0916578D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
CN112587522B (zh) * 2020-12-03 2022-11-25 中国海洋大学 替加色罗在制备用于预防或治疗冠状病毒感染的药物中的应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) * 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) * 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4748234A (en) * 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
JPS6345230A (ja) * 1986-04-01 1988-02-26 Central Glass Co Ltd ブロモベンゾトリフルオリドの製造方法
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
USRE36476E (en) * 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5569644A (en) * 1995-05-18 1996-10-29 The Lubrizol Corporation Additive combinations for lubricants and functional fluids
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US6242414B1 (en) * 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
DE69635051T2 (de) * 1995-06-07 2006-06-14 Chiron Corp Methode zur lösung, reinigung und rückfaltung von protein
US5888968A (en) * 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6011136A (en) * 1995-11-21 2000-01-04 Novartis Ag Cyclopeptolides
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
ATE254472T1 (de) * 1996-03-25 2003-12-15 Chemo Sero Therapeut Res Inst Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
UA55448C2 (uk) * 1997-04-28 2003-04-15 Елі Ліллі Енд Компані Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
WO2000023101A1 (en) * 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
WO2000030677A1 (en) * 1998-11-20 2000-06-02 Eli Lilly And Company Method of treating viral hemorrhagic fever
AU5062100A (en) * 1999-06-14 2001-01-02 Novo Nordisk A/S Fviia/tf activity inhibiting compounds
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
DE60031999T2 (de) * 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
CA2400187A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
WO2002102325A2 (en) * 2001-02-28 2002-12-27 Griffin John H Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
EP1383885A4 (en) * 2001-04-04 2005-11-30 American Diagnostica Inc METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
EP1446140A4 (en) * 2001-10-15 2007-03-07 Novartis Vaccines & Diagnostic TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR)
US20020198138A1 (en) * 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
WO2005110059A3 (en) 2009-04-09
SG150552A1 (en) 2009-03-30
JP2007532486A (ja) 2007-11-15
IL178115A0 (en) 2008-03-20
CN101426520A (zh) 2009-05-06
WO2005110059A2 (en) 2005-11-24
CA2560103A1 (en) 2005-11-24
EP1729791A2 (en) 2006-12-13
BRPI0508992A (pt) 2007-09-04
MXPA06010587A (es) 2007-03-29
ZA200608413B (en) 2008-06-25
TNSN06295A1 (en) 2007-12-03
AU2005244249A1 (en) 2005-11-24
RU2006136267A (ru) 2008-04-27
US20080286279A1 (en) 2008-11-20
KR20070007336A (ko) 2007-01-15

Similar Documents

Publication Publication Date Title
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
Evans et al. Use of angiotensin II for post cardiopulmonary bypass vasoplegic syndrome
Farhan et al. Acquired muscle weakness in the surgical intensive care unit: nosology, epidemiology, diagnosis, and prevention
MXPA04003548A (es) Tratamiento de neumonia severa mediante administracion de inhibidor de via factor de tejido.
NO20053678L (no) Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser
WO2003079979A3 (en) Method for treating congestive heart failure
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
Altschuler et al. Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression
NO931886L (no) Anvendelse av aica ribocid-forbindelser for behandling/prevensjon av vevskader som skyldes nedsatt blodstroemning
NO20051669L (no) Fremgangsmater og reagenser for behandling av sykdommer og forstyrrelser assosiert med okte nivaer av proinflammatoriske cytokiner
NO20064964L (no) Behandling av svekket respiratorisk funksjon
WO2005004854A3 (fr) Utilisation de la betaine pour le traitement des arterites
NO20064674L (no) Behandling av alvorlig lungebetennelse ervervet utenfor sykehus ved administrering av vevsfaktor pathway inhibitor
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2005117937A3 (en) Alpha-1- acid glycoprotein for the treatment of diabetes
CN106389396A (zh) 黄腐酚在防治急性肺损伤与急性呼吸窘迫综合征中的用途
Jafari-Hafshejani et al. Curcumin attenuates oxidative stress-induced effects on TGF-β expression and NF-κB signaling in bovine aortic endothelial cells
NO20075898L (no) Behandling av samfunnsvervet lungebetennelse ved administrering av vevsfaktor pathway inhibitor (TFPI)
Sung Management of nonsteroidal anti-inflammatory drug–related peptic ulcer bleeding
TNSN07386A1 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
BR112023024210A2 (pt) Comprimido efervescente orodispersível contendo budesonida para uso no tratamento de esofagite eosinofílica
Nemoto et al. Oral sildenafil ameliorates impaired pulmonary circulation early after bidirectional cavopulmonary shunt
RU2762945C1 (ru) Способ антикоагулянтной терапии и профилактики тромботических осложнений у пациентов с тяжелым повреждением головного мозга в хроническом критическом состоянии
Wohlrab et al. Iloprost in dermatology
Mancia et al. EARLY BLOOD PRESSURE CONTROL BY THE NIFEDIPINE GITS/TELMISARTAN COMBINATION: PP. 33.314

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application